A Phase I/II, Modular, Open-Label, Multi-Centre Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD9750 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Metastatic Prostate Cancer (ANDROMEDA)
Latest Information Update: 27 Jan 2026
At a glance
- Drugs AZD 9750 (Primary) ; Saruparib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms ANDROMEDA
- Sponsors AstraZeneca
Most Recent Events
- 27 Jan 2026 New trial record